Q-linea AB (publ) (STO:QLINEA)

Market Cap	401.71M +128.0%
Revenue (ttm)	19.46M +370.2%
Net Income	-182.49M
EPS	-27.40
Shares Out	18.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,938
Average Volume	5,006
Open	21.20
Previous Close	20.90
Day's Range	20.90 - 21.40
52-Week Range	20.79 - 79.00
Beta	0.66
RSI	39.42
Earnings Date	Apr 24, 2026

About Q-linea AB

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture unit for incu...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Employees: 82
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QLINEA

Financial Performance

In 2025, Q-linea AB's revenue was 19.46 million, an increase of 370.16% compared to the previous year's 4.14 million. Losses were -182.49 million, -15.86% less than in 2024.